For Scientists

Results Videos

Blood-Biomarker to stratify Cirrhosis Patients in the ALB-Trial

Nikolaj Torp (MD), ALB Trial coordinator and PhD student in the group of Prof. Aleksander Krag at Odense University Hospital (OUH) in Denmark, describes the number of patients, participating countries, study duration and biomarker-based stratification process that cirrhosis patients undergo after being included in MICROB-PREDICT’s albumin trial (ALB-TRIAL).

Metagenomics-Metaproteomics Pipeline for Biomarker Discovery in ACLF 

Peter Treit, a PhD Candidate in Matthias Mann’s group at the Max-Planck Institute of Biochemistry in Munich, Germany, describes the collaborative pan-European data pipeline of the MICROB-PREDICT consortium from bio-sampling to sample analysis (including metagenomics, transcriptomics, and metaproteomics) to assemble a multi-omics biomarker panel for ACLF and to build reliable predictive models for optimal patient stratification and treatment selection.

Multi-Omics Biomarkers for Early Identification of Pre-ALCF

Camila Alvarez-Silva (PhD), a postdoctoral researcher in the group of Mani Arumugam at the University of Copenhagen, Denmark, presents the approach and first results of a multi-omics study to identify biomarkers for early identification of PreALCF patients.

The predictive Role of Immunoglobulins in Gut Barrier Dysfunction

Dávid Tornai (MD, PhD) from the University of Debrecen presents his recent data on the predictive role of immunoglobulins, especially secretory IgA, indicative of gut barrier dysfunction in a prospective patient cohort with cirrhosis and acute decompensation.

Serum Villin-1, a tell-tale Sign of Gut-Barrier Failure in Cirrhosis

Dávid Tornai (MD, PhD) from the University of Debrecen presents his recent data on serum villin-1 level, a tell-tale sign of gut barrier failure in cirrhotic patients with acute decompensation.

The Gut Virome and Bacteriophages in Decompensated Liver Cirrhosis

Lore Van Espen, PhD candidate in the group of Prof. Jelle Matthijnssens at KU Leuven in Belgium, presents exciting data on the gut virome, particularly on phages (bacteria-infecting viruses) in the gut of patients with decompensated liver cirrhosis.

Albumin reduces Inflammation & protects against Multi-Organ Injury

Alexandra Phillips, a PhD candidate in the group of Rajiv Jalan at University College London (UCL), United Kingdom, presents her pre-clinical and translational research in animal models of liver failure and ACLF, particularly how albumin infusions reduce endotoxin sensitivity by modulating TLR4-related inflammation, and how albumin protects against multi-organ injury in these animals. Research in these animal models is absolutely crucial to identify biological targets and to develop much-needed treatment options for humans suffering from advanced cirrhosis or ACLF, many of whom – unfortunately – still die if they do not receive a liver transplant because there are still no effective treatments available.

Multi-Compartment Metabolomics to stratify Cirrhotic Patients

Christoph Junot, head of the Drug Metabolism Research Laboratory at CEA in France describes the multi-compartment metabolomics approach used by his research team to discover novel biomarkers for decompensated cirrhosis and ACLF in blood plasma, urine, and stool samples.

Leukotoxin 9,10-DiHOME drives Immunosuppression in ACLF

Cristina López Vicario and Bryan Contreras Herrera, a senior postdoc and her PhD student in the “Inflammation and Liver Disease” group of Prof. Joan Clària at IDIBAPS in Barcelona, Spain, describe their molecular biology results about the immunosuppressive actions of the linoleic acid derivate 9,10-DiHOME (9,10-dihydroxy-12Z-octadecenoic acid), a leukotoxin that appears to drive inflammation and a cirrhotic patient’s susceptibility to bacterial infection during late-stage liver cirrhosis.